Novo Nordisk's Pipeline Paradox: Semaglutide Scores in Children While Ziltivekimab's Heart Failure Programme Collapses

Novo Nordisk's STEP Young trial hits its goal in children, but two ziltivekimab heart failure trials are halted ahead of its 21 September capital markets day.

Two announcements landed within days of each other this week, and they pull Novo Nordisk's investment case in opposite directions. On one side sits a genuine scientific milestone in paediatric obesity; on the other, a quiet but telling retreat from a cardiovascular programme that was supposed to broaden the company's horizons beyond diabetes and weight loss.

A milestone in the youngest patients

Monday brought word that the Phase 3 STEP Young trial had cleared its primary endpoint. Among children aged six to under twelve with obesity, 40.4 percent of those treated with semaglutide alongside lifestyle changes no longer met the criteria for an obesity diagnosis after 68 weeks. Safety and tolerability profiles tracked with earlier semaglutide and liraglutide studies, according to the company.

For a business whose entire commercial engine runs on the efficacy of GLP-1 therapies, the result opens a door into territory that has remained largely uncharted: treating obesity in pre-adolescents. It is, by any reasonable measure, a breakthrough — yet it covers a patient population whose commercial weight will not be felt for years.

The other side of the pipeline

While that news was still settling, Novo Nordisk disclosed that it had halted two additional Phase 3 trials of ziltivekimab in heart failure. An independent data monitoring committee, after reviewing interim data, concluded that a result diverging from the previously failed cardiovascular study was unlikely. Investigators had already been notified the previous Friday, with the public announcement following on Monday, as Reuters reported.

The significance lies less in a single molecule than in what it signals. The first ziltivekimab setback now looks less like an outlier and more like a symptom of a deeper problem with the candidate. One study remains active — testing ziltivekimab in patients after acute myocardial infarction — with data expected in the first half of 2027. That is a glimmer of clarity, but it is more than a year away.

Diversification under strain

This is the crux of the Novo Nordisk story right now: real scientific progress arrives, but rarely without collateral damage. The paediatric data are impressive, yet they address a segment that will not matter commercially for years. The heart failure pipeline, by contrast, was meant to help the company build a portfolio beyond diabetes and obesity — and that is precisely where the cracks are showing.

The question investors face is not whether one molecule fails, but whether the pipeline is broad enough to absorb such setbacks without undermining the growth narrative.

Germany as a tablet test case

Roughly a week ago, Novo Nordisk launched the Wegovy tablet in Germany, extending the oral semaglutide rollout to another European market — the first EU market for the pill form. Strategically coherent, certainly. But the share price has slipped since then, down around 4.3 to 4.4 percent, suggesting the market had already priced in the expansion or doubts its ability to move the needle.

Broader context explains the muted reaction. On 2 September, Citi reaffirmed a sell rating with a price target of DKK 265, citing weakening GLP-1 prescription trends in weekly IQVIA data — with one exception: the oral Wegovy variant. The very product now launching in Germany stands out as one of the few bright spots in an otherwise dimming prescription picture.

Market data reflect the mixed sentiment. At a closing price of EUR 38.37, the stock sits roughly 30 percent below its 52-week high of EUR 54.86 set in January, yet still about 27 percent above its early-March low. Year-to-date, shares are down 13 percent; over twelve months, 17 percent. An RSI of 39.6 does not signal extreme oversold conditions but points to persistently weak momentum — consistent with annualised volatility of 40 percent, a measure of how nervously the market is pricing the company.

What London must deliver

On 21 September, Novo Nordisk hosts a capital markets day in London, where management intends to present strategy, research pipeline, operational setup and business development. For a company navigating between a paediatric breakthrough, a discontinued heart failure programme and declining prescriptions for its established products, the event is more than routine.

It will need to demonstrate whether the diversification strategy — from childhood obesity to the oral tablet — carries enough substance to dispel the doubts already visible in the IQVIA numbers and the share price. Management must explain how the paediatric successes and the remaining heart failure study fit into a convincing medium-term growth story that reaches beyond the diabetes-obesity duopoly.

Until then, the stock remains what it currently is: a mirror of contradictory signals, resistant to resolution in any single direction. Good news lands selectively; bad news echoes broadly. Skepticism prevails — not because the pipeline is weak, but because the market is weighing every advance against existing doubts rather than treating it as a standalone signal. The capital markets day will show whether that changes.